Aardvark Therapeutics, Inc.
AARD
$13.94
$0.382.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -252.14% | -211.10% | -252.81% | -185.63% | -- |
| Total Depreciation and Amortization | -48.44% | -110.87% | -423.81% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104.44% | -25.67% | -35.91% | -28.94% | -- |
| Change in Net Operating Assets | 27.00% | 122.97% | -172.73% | 2,041.98% | -- |
| Cash from Operations | -291.53% | -259.87% | -321.55% | -210.56% | -- |
| Capital Expenditure | 1.94% | -4.08% | -1,980.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -83,263.11% | -117,364.29% | -2,492,240.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54,056.80% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -64.70% | -78.19% | -- | -- | -- |
| Cash from Financing | 5.97% | 5.92% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.22% | -181.65% | 392.77% | 991.24% | -- |